Painless eye drops aim to save sight in kids with brain tumors
NCT ID NCT05733572
First seen Mar 20, 2026 · Last updated May 01, 2026 · Updated 4 times
Summary
This study tests whether a new, painless form of nerve growth factor (called CHF6467) given as eye drops can protect vision in children and young adults with optic pathway glioma, a type of brain tumor that often causes vision loss. The trial involves 36 participants aged 3 to 40 who will receive either the active eye drops or a placebo. The goal is to see if the drops are safe and can slow or prevent further vision damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPTIC PATHWAY GLIOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Catholic University, Policlinico A. Gemelli (Hospital)
Rome, 00168, Italy
Conditions
Explore the condition pages connected to this study.